{"filing":{"accession_number":"0001193125-26-332809","cik":"0001637715","ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"okur-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/okur-20260804.htm"},"events":[{"id":23899,"run_id":21616,"accession_number":"0001193125-26-332809","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"OnKure Therapeutics issued a press release on August 4, 2026, reporting financial results for the quarter ended June 30, 2026, including R\u0026D expenses of $12.6 million, G\u0026A expenses of $4.3 million, net loss of $15.3 million ($0.31 per share), and cash position of $176.4 million. The filing explicitly discloses Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24257,"accession_number":"0001193125-26-332809","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"OnKure Therapeutics issued a press release on August 4, 2026, reporting financial results for the quarter ended June 30, 2026, including R\u0026D expenses of $12.6 million, G\u0026A expenses of $4.3 million, net loss of $15.3 million ($0.31 per share), and cash position of $176.4 million. The filing explicitly discloses Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:26:16.587803+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24257,"accession_number":"0001193125-26-332809","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"OnKure Therapeutics issued a press release on August 4, 2026, reporting financial results for the quarter ended June 30, 2026, including R\u0026D expenses of $12.6 million, G\u0026A expenses of $4.3 million, net loss of $15.3 million ($0.31 per share), and cash position of $176.4 million. The filing explicitly discloses Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:26:16.587803+00:00","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-08-04"}]}